Cargando…
Is sirolimus a therapeutic option for patients with progressive pulmonary lymphangioleiomyomatosis?
BACKGROUND: Lymphangioleiomyomatosis (LAM) is a rare lung disease characterised by progressive airflow obstruction. No effective medical treatment is available but therapy with sirolimus has shown some promise. The aim of this observational study was to evaluate sirolimus in progressive LAM. METHODS...
Autores principales: | Neurohr, Claus, Hoffmann, Anna L, Huppmann, Patrick, Herrera, Vivian A, Ihle, Franziska, Leuschner, Stefan, von Wulffen, Werner, Meis, Tobias, Baezner, Carlos, Leuchte, Hanno, Baumgartner, Rainer, Zimmermann, Gregor, Behr, Juergen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3116484/ https://www.ncbi.nlm.nih.gov/pubmed/21600034 http://dx.doi.org/10.1186/1465-9921-12-66 |
Ejemplares similares
-
Effects of Sirolimus on Lung function in patients with Lymphangioleiomyomatosis
por: Aghaeimeybodi, Fatemeh, et al.
Publicado: (2019) -
Efficacy and safety of low-dose Sirolimus in Lymphangioleiomyomatosis
por: Yoon, Hee-Young, et al.
Publicado: (2018) -
Unexpected sirolimus-stimulated airway hyperreactivity in lymphangioleiomyomatosis
por: Steagall, Wendy K., et al.
Publicado: (2023) -
Functional improvements in patients with lymphangioleiomyomatosis after sirolimus: an observational study
por: Zhan, Yongzhong, et al.
Publicado: (2018) -
Long-term efficacy and safety of sirolimus therapy in patients with lymphangioleiomyomatosis
por: Hu, Siqi, et al.
Publicado: (2019)